MCA Risk:benefit analysis of Kava-kava Update as at 12 Feb 2002.

Slides:



Advertisements
Similar presentations
The management of adverse drug reactions I Ralph Edwards
Advertisements

Safety Reporting IN Clinical Trials
Applying the Nursing Process to Drug Therapy
Artesunate Rectal Capsules For the initial management of acute malaria in patients who cannot take medication by mouth and for whom parenteral treatment.
Deriving Biological Inferences From Epidemiologic Studies.
Overview of Aspirin and NSAID’s Label Warnings William E. Gilbertson, PharmD. Division OTC Drug Products 1.
Nonprescription Simvastatin in the United Kingdom Michael L. Koenig, Ph.D. Interdisciplinary Scientist Division of Over-the-Counter Drug Products Center.
FEDERAL REGULATIONS OF MEDICATIONS Food, Drug and Cosmetic Act Protect consumers from adulterated and misbranded foods, drugs, cosmetics, or devices.
Special Topics in IND Regulation
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
Basic Pharmacovigilance Training
Overview of Acetaminophen Label Warnings William E. Gilbertson, PharmD. Division OTC Drug Products 1.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Clinical causality assessment I. Ralph Edwards R.H.B Meyboom.
Regulation of Promotion of Prescription Drugs Thomas W. Abrams, R.Ph., MBA Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
CHEE DRUG PRODUCT DEVELOPMENT u Drug ä agent intended for use in the diagnosis, mitigation, treatment, cure, or prevention of disease in man or animals.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Introduction to Pharmacology PHARM TECH. Pharmacology  Pharmacology is the science that deals with the study of therapeutic (beneficial) agents.  Knowledge.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 7 Over-the-Counter Drugs and Herbal and Dietary.
DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Dispensary and Administration Site Information Presentation.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
CAUSALITY ASSESSMENT OF SUSPECTED AEs Dr. Retesh Kumar Head, Global PhV Department 12/13/2015.
What pharmacovigilance can do for you! relationship assessment is a better concept 24 Nov Dar es Salaam.
FDA Regulatory and Compliance Symposium
Good Pharmacovigilance Practices
Investigational Devices and Humanitarian Use Devices June 2007.
Signal identification and development I.Ralph Edwards.
Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.
Joanne Edwards Medical Information Manager ASCO Tech Assessment Update Commercial Implications & Promotional Guidance.
Off Label Use in Managed Care Pharmacy Presentation Developed for the Academy of Managed Care Pharmacy Updated February 2015.
Effets indesirables des médicaments Cours en partie basé sur source documentaire de l’OMS.
OVER THE COUNTER MEDS INTRODUCTION No prescriptions are necessary and no questions need to be answered to attain these drugs OTC med use saves.
Addressing Tobacco Use in Mental Health Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester.
Addressing Tobacco Use in Medical Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester School.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
1 Pharmacovigilance & the New National Adverse Drug Reaction (ADR) Reporting System Michael Bonett, Quality Assessor Post-Licensing Directorate Medicines.
Off-Label Use in Managed Care Pharmacy Presentation Developed for the Academy of Managed Care Pharmacy Updated: February 2016.
Focus On Nonvitamin/ Nonmineral Supplements. Copyright 2010, John Wiley & Sons, Inc. Types of Dietary Supplements.
PHARMACEUTICAL GUIDELINES: BASIC PRINCIPLES AND STATUTES.
Drug Induced Liver Injury
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Dental prescription prepared by : Dr.Roba Alagha
Detection & monitoring of ADR
Copyright © 2016 by Mosby, an imprint of Elsevier Inc.
8. Causality assessment:
Safety Reporting Nichol McBee, MPH, CCRP.
Within Trial Decisions: Unblinding and Termination
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
9. Introduction to signal detection
Antineoplastic Medications
The Nursing Process and Pharmacology Jeanelle F. Jimenez RN, BSN, CCRN
Pharmacovigilance (PV)
SERIOUS ADVERSE EVENTS REPORTING
Reporting to the CPHS: Unanticipated Problems & Serious Adverse Events
Causality assessment Using causality models
PROSES TERAPI DAN PERMASALAHANNYA
Compounded Drugs and Lack of Premarket FDA-Approval
Clinical presentation of terbinafine-induced severe liver injury and the value of laboratory monitoring: a critically appraised topic O.N. Kramer BS;1.
Presentation transcript:

MCA Risk:benefit analysis of Kava-kava Update as at 12 Feb 2002

MCA Update on worldwide situation Germany -Have not yet finalised their assessment. -Expert group has recommended that it becomes a Prescription Only Medicine. France -Have suspended products from sale (includes homeopathics down to a 1/500 dilution) Ireland -Have voluntarily removed from sale all licensed and unlicensed Kava containing products

MCA Worldwide update cont. Portugal -Have suspended all kava containing products including homeopathics for 1 year. USA -Distributed a “Dear Doctor” letter requesting doctors to review all cases of hepatotoxicity to identify whether patients were taking Kava. -Consumers have been recommended not to take products containing Kava. Canada -Distributed information recommending that consumers should not use Kava containing products until the risks have been assessed.

MCA Worldwide update cont. Australia -Investigating the safety of Kava. -Consumers have been recommended not to take Kava containing products. New Zealand -3 cases of hepatitis possibly associated with Kava. -Initiating a toxicology review. -Kava products are still on sale.

MCA Scientific Analysis Additional useful data -List of products on the UK market. -Any further efficacy data. Efficacy data already available -Meta-Analysis by Pittler and Ernst. -Review of risk:benefit profile of herbals by Ernst -Published studies

MCA Analysis of case reports by herbal interest groups The majority of submissions included an analysis of the cases reports. The conclusions often differed between submissions. No consistent criteria for causality were used.

MCA Criteria of causality - example of method used by MCA Certain -A clinical event, including a laboratory test abnormality, that occurs in a plausible time relation to drug administration, and which cannot be explained by coincidental or concurrent disease or other drugs or chemicals. -The response to withdrawal of the drug (dechallenge) should be clinically plausible e.g. the patient recovers. -The event must be definitive pharmacologically or phenomenologically, using a satisfactory rechallenge procedure if necessary.

MCA Probable -A clinical event, including a laboratory test abnormality, with a reasonable time relation to administration of the drug. -unlikely to be attributed to concurrent disease or to other drugs or chemicals. -which follows a clinically reasonable response on withdrawal (dechallenge). -Rechallenge information is not required to fulfil this definition.

MCA Possible -A clinical event, including a laboratory test abnormality, with a reasonable time relation to administration of the drug. -which could also be explained by concurrent disease or other drugs or chemicals. -Information on drug withdrawal may be lacking or unclear. Unlikely -A clinical event, including a laboratory test abnormality, with a temporal relation to administration of the drug. -which makes a causal relation improbable, and in which other drugs, chemicals, or underlying disease provide plausible explanations.

MCA Unassessable -A report suggesting an adverse reaction that cannot be judged, because information is insufficient or contradictory and cannot be supplemented or verified. Note: these are possible criteria for causality assessment of suspected adverse drug reactions derived from a paper published in the Lancet 2000; 356:

MCA Case number 10 - example of “probable” case 39 year old female Taking a standard extract product (unspecified) Experienced hepatitis and confluent necrosis ADR confirmed by laboratory tests Past medical history -stable on hormone ovulation inhibitor for 6 years (hepatic reactions associated with this medicine but not in this patient) -also taking paroxetine and St John’s wort PRN The consumer took the kava product and experienced the ADR, then recovered when all medication was stopped -Positive dechallenge Some months later the consumer restarted the Kava and experience hepatic ADRs 14 days later -Positive rechallenge

MCA Case number 17 - example of “possible” case 60 year old female Taking a standard acetone-extract product at the recommended dose 3x70mg per day 3 weeks after starting the kava preparation the patient experienced hepatic ADRs ADRs confirmed by laboratory tests Good temporal relationship Other drugs -Celecoxib taken PRN (hepatic reactions associated with this medicine) The consumer stopped the Kava preparation and recovered within 2 weeks -Positive dechallenge

MCA Some provisional pointers The mechanism of toxicity has not been determined The onset of hepatic reactions appears unpredictable No data has been put forward to identify what might be a “safe dose” There is insufficient data to support general efficacy Some of the cases suggest a “possible/probably” association between hepatic reactions and Kava

MCA Possible regulatory options where there is a herbal safety issue Prohibition -Prohibit the ingredient in unlicensed medicines (e.g. as was done with Aristolochia). Prescription Only Medicine -Make the ingredient a prescription only medicine (POM). Restrict usage - e.g. set a maximum dosage.

MCA Possible regulatory options (contd) Add warnings (e.g. regarding rare hepatic adverse reactions) -Initiate variations for the 3 licensed products. -Obtain voluntary agreement with manufacturers of unlicensed products to include warning information Take no regulatory action at this time

MCA Example of possible labelling ( based on suggestions from the herbal sector ) Do not take this product if you have a history of liver problems or in combination with alcohol or medication, unless under the guidance of your doctor. This product may rarely cause liver problems with symptoms such as jaundice, brown urine, nausea, vomiting and unusual tiredness. If you experience an adverse effect while taking this product please consult your doctor.